

JON OTTER PhD, FRCPath

EDUCATION

Consultant Clinical Scientist (AHCS Scientific Training Programme Equivalence, 2022; AHCS Higher Specialist Scientist Equivalence, 2023).

Fellow of the Royal College of Pathologists (FRCPath) (2014).

PhD, King's College London, UK (part-time) (2005-2011). '[*The molecular epidemiology of community-associated MRSA at a London Teaching Hospital*](#)'.

BSc (Hons) Microbiology (1st), University of Nottingham, UK (1998-2001).

EMPLOYMENT

Jul 21 - present: Guy's and St. Thomas' NHS Foundation Trust, London

Joint Director of Infection Prevention and Control covering adult and community services at Guy's and St. Thomas' Hospitals, Evelina London Children's Hospital, and Royal Brompton and Harefield Hospitals. I lead a multidisciplinary team to deliver a range of functions including IPC nursing, surveillance and innovation, vascular access, environmental IPC, and applied research.

Oct 15 - present: Imperial College London

Honorary Senior Lecturer in the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Imperial College London, which is situated with the Department of Medicine. Research interests include the epidemiology of MRSA, *C. difficile* and multidrug-resistant Gram-negatives, antibiotic and antiseptic resistance, the role of contaminated surfaces in transmission, and molecular typing methods including some recent dabbling in whole genome sequencing.

Apr 19 - Apr 22: NIHR Imperial College London Biomedical Research Centre (BRC) (part-time)

Post-doc Research Fellow investigating the development of antimicrobial surfaces to tackle HCAI and AMR.

Apr 15 – Jul 21: Imperial College Healthcare NHS Trust, London

Managed the Infection Prevention and Control and Antimicrobial Stewardship Service. I led a multidisciplinary team of 25 expert doctors, nurses, data scientists, technical experts, and administrators to deliver an Infection Prevention and Control service across a group of five hospitals in central London. Also tasked with implementing the findings of an ambitious research programme at Imperial College London in conjunction with Public Health England to improve clinical practice.

Mar 10 – Mar 15: Centre for Clinical Infection and Diagnostics Research (CIDR) (King's College London / Guy's and St. Thomas' NHS Foundation Trust, London) (part-time)

Post-doc Research Fellow investigating the epidemiology of key healthcare-associated pathogens including MRSA, *C. difficile*, and resistant Gram-negatives.

Dec 02 – Mar 15: Bioquell UK Ltd, Andover, Hampshire, UK (part-time from 2005)

Scientific Director of Bioquell's Healthcare division, responsible for delivering a high-quality research programme evaluating the impact of Bioquell's products in the healthcare setting.

May – Oct 07: Johns Hopkins Hospital, USA (secondment)

During this secondment I initiated a high-profile study, which demonstrated that Bioquell's HPV product mitigates the increased risk from the prior room occupant (Passaretti *et al. Clin Infect Dis* 2013; 56:27-35).

May – Oct 05: Yale-New Haven Hospital, St. Raphael Campus, USA (secondment)

Seconded to initiate a successful high-profile research project investigating the environmental and clinical impact of regular decontamination using Bioquell's HPV product (Boyce *et al. Infect Cont Hosp Epidemiol* 2008;29:723-729).

Mar – Sept 03: St. Thomas' Hospital, Department of Infection, London (secondment)

Seconded to conduct an intervention study to investigate and compare the impact of conventional cleaning with Bioquell's HPV product (French *et al. J Hosp Infect* 2004;57:31-37).

PROFESSIONAL ACTIVITY

- NHS National Infection Prevention and Control Policy (NIPCP) Manual Oversight and Consensus Groups (2022-present).
- Member of the expert group led by PHE to update national recommendations for the prevention and control of CPE (2018-2021).
- Research Director for [Clean Hospitals](#) (2018-2021).
- Member of the Interclean Healthcare Forum planning committee (2016-2020).
- Collaborator with the Antimicrobial Research Collaborative (ARC) and Institute for Molecular Science and Engineering (IMSE) at Imperial College London (2015-present).
- Assistant Editor for the Journal of Hospital Infection (2011-2016).
- Member of the Healthcare Infection Society (HIS) Scientific Programme Committee (2015-2016)
- Member of the Infection Prevention Society (IPS) Scientific Programme Committee (2010-2015).
- Visiting Professor at the Tokyo Healthcare University, Japan (2011-2012).
- IPS representative on the British Society for Antimicrobial Chemotherapy (BSAC) multiresistant Gram-negative bacterial infection Working Group.
- British Standards Institute (BSI) representative on a working group developing a European testing standard for airborne disinfection.
- Peer-reviewer for the Lancet, Lancet Infectious Diseases, British Medical Journal, Journal of Hospital Infection, Infection Control and Hospital Epidemiology, American Journal of Infection Control, Journal of Infection Prevention, Clinical Microbiology and Infection and the European Journal of Clinical Microbiology and Infectious Diseases.

- Member of the Healthcare Infection Society (HIS), Infection Prevention Society (IPS), Society for Healthcare Epidemiologists of America (SHEA) and the Association for Professionals in Infection Control (APIC).
- Author for EIDO Healthcare (patient information leaflets).

GRANTS / AWARDS

- 2020-2025. NIHR Health Protection Research Unit (HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Imperial College. NHS lead for Practice, Design, and Engineering theme.
- 2019-2021. *'Developing "smart" liquid antimicrobial surfaces' for reducing the transmission of hospital pathogens and reducing antibiotic resistance.* NIHR Imperial Biomedical Research Centre (BRC): Post-doctoral Fellowship. Principle Investigator. £50k.
- 2017. *'Developing "smart" antimicrobial copper-based surfaces to reduce the transmission of antibiotic-resistant hospital pathogens'*. EPSRC. Principle Investigator. £1k.
- 2014-2015. *'Enhanced carbapenem-resistant organism surveillance.'* Guy's and St. Thomas' Charity. Principle Investigator. £130k.
- 2014-2015. *'Evaluation of community-based prevalence and transmission of antibiotic resistant Gram-negative bacteria.'* Guy's and St. Thomas' Charity. Co-applicant. £100k.
- 2014-2015. *'Hydrogen Peroxide Vapor (HPV) Decontamination for Reuse of N95 Respirators'*. US FDA. Co-applicant. \$450k.
- 2011-2012. *'Epidemiology and virulence of CA-MRSA'*. Pfizer Europe Aspire 2010 Investigator Award in Antibacterial Research. Principle Investigator. £67k.
- 2009-2012. *'Characterisation, molecular epidemiology and control of evolving strains of MRSA in a London Teaching Hospital and its local community.'* Guy's and St. Thomas' Charity. Co-applicant. £294k.
- 2005-2009. Royal Commission for the Exhibition of 1851 PhD Fellowship. Principle Investigator. 80k.

PAPERS

* = joint first authors.

Davidson HC, Griffin AE, Symes L, Laing KG, Witney AA, Gould K, Allebone-Salt P, Abadioru O, Goldenberg SD, Otter JA, Wake R, Bicanic T. Detection of *Candidozyma* (formerly *Candida*) *auris* from ward wastewater during an outbreak using culture and molecular methods. *J Hosp Infect* 2026;167:199-203.

Almadhoon H, Ahmad I, Lee WWY, Matthews A, Carter ER, Otter JA, Lecky DM, Holmes AH, Zhu NJ. Prevalence of carbapenem-resistant Enterobacterales in healthcare and community settings in the UK: a systematic review and meta-analysis. *J Hosp Infect* 2025;165:19-31.

Snell LB, Hussein A, Abadioru O, Dibbens M, Whitehorn J, Nichols R, May L, Coates S, Barrett NA, Winteridge H, Otter JA, Goldenberg SD. Use of continuous remote sensor water temperature monitoring to rationalize provision of clinical handwash basins in an ICU with water safety issues. *J Hosp Infect* 2025 Nov;165:1-8.

Atkinson B, Gould S, Nicholls I, Manzoor KN, Smith J, Hindle AJ, Tunbridge AJ, Cole J, Collini P, Alonso A, O'Hara G, Tuudah C, Otter JA, Hack B, Taylor C, Pottage T, Fletcher T, Dunning J. Air and surface sampling for clade Ib monkeypox virus in United Kingdom hospitals, 2024 to 2025. *Euro Surveill* 2025;30:2500288.

Kiernan MA, Garvey M, Norville P, Otter JA, Weber DJ. Response to Dr Dancer. *J Hosp Infect* 2025 Feb;156:131-132

Snell LB, Prossomariti D, Alcolea-Medina A, Sasson M, Dibbens M, Al-Yaakoubi N, Humayun G, Charalampous T, Alder C, Ward D, Maldonado-Barrueco A, Abadioru O, Batra R, Nebbia G, Otter JA, Edgeworth JD, Goldenberg SD. The drainome: longitudinal metagenomic characterization of wastewater from hospital ward sinks to characterize the microbiome and resistome and to assess the effects of decontamination interventions. *J Hosp Infect* 2024;153:55-62. 3

Sharrocks K, Prossomariti D, Snell LB, Dibbens M, Alcolea-Medina A, Gargee L, Marashi J, Edgeworth JD, Otter JA, Goldenberg SD. Use of a peracetic acid (PAA) disinfectant to reduce total viable bacteria count in hospital wastewater drains. *J Hosp Infect* 2024;151:79-83.

Wan Y, Myall AC, Boonyasiri A, Bolt F, Ledda A, Mookerjee S, Weiße AY, Getino M, Turton JF, Abbas H, Prakapaite R, Sabnis A, Abdolrasouli A, Malpartida-Cardenas K, Miglietta L, Donaldson H, Gilchrist M, Hopkins KL, Ellington MJ, Otter JA, Larrouy-Maumus G, Edwards AM, Rodriguez-Manzano J, Didelot X, Barahona M, Holmes AH, Jauneikaite E, Davies F. Integrated Analysis of Patient Networks and Plasmid Genomes to Investigate a Regional, Multispecies Outbreak of Carbapenemase-Producing Enterobacterales Carrying Both bla_{IMP} and mcr-9 Genes. *J Infect Dis* 2024 25;230:e159-e170.

Brown L, Marshall A, Conway L, Otter JA, Norville P, Clarke J. Assessing the stability and sporicidal efficacy of oxidizing disinfectants. *J Hosp Infect* 2024;149:22-25.

Norville P, Otter JA. The requirement to move towards standardization of wastewater sampling. *J Hosp Infect* 2024;149:88-89.

Kiernan MA, Garvey MI, Norville P, Otter JA, Weber DJ. Is detergent-only cleaning paired with chlorine disinfection the best approach for cleaning? *J Hosp Infect* 2024;148:58-61.

Okeke N, Snell LB, Rathish B, Hussein A, Newsholme W, Mack D, Breathnach A, Otter JA. Evaluating the dynamics of hospital COVID-19 contacts and subsequent conversion to SARS-CoV-2 infection: a multi-centre retrospective cohort study. *Infect Prev Pract* 2023 10;6:100325.

Otter JA, Clark L, Taylor G, Hussein A, Gargee L, Goldenberg SD. Comparative evaluation of stand-alone HEPA-based air decontamination systems. *Infect Dis Health* 2023;28:246-248.

Vasikasin V, Rawson TM, Holmes AH, Otter JA. Can precision antibiotic prescribing help prevent the spread of carbapenem resistant organisms in the hospital setting? *J Antimicrob Chemother* 2023;5:dlad036.

Rochon M, Jawarchan A, Fagan F, Otter JA, Tanner J. Image-based digital post-discharge surveillance in England: measuring patient enrolment, engagement, clinician response times, surgical site infection and carbon footprint. *J Hosp Infect* 2023;133:15-22.

Otter JA*, Zhou J*, Price JR, Reeves L, Zhu N, Randell P, Sriskandan S, Barclay W, Holmes AH. SARS-CoV-2 surface and air contamination in an acute healthcare setting during the first and second pandemic waves. *J Hosp Infect* 2023;132:36-45.

Otter JA, Newsholme W, Snell LB, Merrick B, Okeke N, Mack DJF, Breathnach AS, Price NM. Evaluation of clinical harm associated with Omicron hospital-onset COVID-19 infection. *J Infect* 2023;86:66-117.

Robinson J, Price L, Otter JA, Burnett E. Designing an optimal infection prevention service: Part 2. *J Infect Prevent* 2023;24:11-22.

Zhu NJ, Rawson TM, Mookerjee S, Price JR, Davies F, Otter JA, Aylin P, Hope R, Gilchrist M, Shersing Y, Holmes A. Changing Patterns of Bloodstream Infections in the Community and Acute Care Across 2 Coronavirus Disease 2019 Epidemic Waves: A Retrospective Analysis Using Data Linkage. *Clin Infect Dis*. 2022 Aug 24;75(1):e1082-e1091.

Ledwoch K, Dancer SJ, Otter JA, Maillard JY. Dirty QWERTY: there's no ESC! *J Hosp Infect*. 2021 Nov;117:184-185.

Graves N, Mitchell BG, Otter JA, Kiernan M. The cost effectiveness of temporary single rooms to reduce the risk of healthcare-associated infection. *J Hosp Infect* 2021; 116: 21-28.

Abbas M, Zhu NJ, Mookerjee S, Bolt F, Otter JA, Holmes AH, Price JR. Hospital-onset COVID-19 infection surveillance systems: A systematic review. *J Hosp Infect* 2021;15:44-50.

Ledwoch K, Dancer SJ, Otter JA, Kerr K, Roposte D, Maillard J-Y. How dirty is your QWERTY? The risk of healthcare pathogen transmission from computer keyboards. *J Hosp Infect* 2021;112:31-36.

Martischang R, Tartari E, Kilpatrick C, Mackenzie G, Carter V, Castro-Sánchez E, Márquez-Villarreal H, Otter JA, Perencevich E, Silber D, Storr J, Tetro J, Voss A, Pittet D. Enhancing engagement beyond the conference walls: analysis of Twitter use at #ICPIC2019 infection prevention and control conference. *Antimicrob Resist Infect Control*. 2021;10:20.

Castro-Sánchez E, Alexander CM, Atchison C, Patel D, Leung W, Calamita M, Meno Garcia D, Cimpeanu C, Mumbwatasai JM, Ramid D, Doherty K, Grewal HS, Otter JA, Wells M. Evaluation of a

personal protective equipment (PPE) support programme ('PPE Helpers') for staff during the COVID-19 pandemic in London. *J Hosp Infect* 2021;109:68-77.

Otter JA, Mookerjee S, Davies F, Bolt F, Dyakova E, Shersing Y, Boonjasiri A, Weise AY, Gilchrist M, Galletly TJ, Brannigan ET, Holmes A. Detecting CPE – an evaluation of an enhanced CPE infection control and screening programme in acute care. *J Antimicrob Chemother* 2020;75:2670-2676.

Zhou J*, Otter JA*, Price JR, Cimpeanu C, Meno Garcia D, Kinross J, Boshier P, Mason S, Bolt F, Holmes AH, Barklay W. Investigating SARS-CoV-2 surface and air contamination in an acute healthcare setting during the peak of the COVID-19 pandemic in London. *Clin Infect Dis* 2021;73:e1870-e1877.

Price JR*, Mookerjee S*, Dyakova E, Myall A, Leung W, Weiße AY, Shersing Y, Brannigan ET, Galletly T, Muir D, Randell P, Davies F, Bolt F, Barohona M, Otter JA, Holmes AH. Development and delivery of a real-time hospital-onset COVID-19 surveillance system using network analysis. *Clin Infect Dis* 2021;72:82-89.

Rodriguez-Manzano J, Moser N, Malpartida-Cardenas K, Moniri A, Fisarova L, Pennisi I, Boonyasiri A, Jauneikaite E, Abdolrasouli A, Otter JA, Bolt F, Davies F, Didelot X, Holmes A, Georgiou P. Rapid Detection of Mobilized Colistin Resistance using a Nucleic Acid Based Lab-on-a-Chip Diagnostic System. *Sci Rep* 2020;21;10(1):8448.

Peters A, Parneix P, Otter JA, Pittet D. Putting some context to the aerosolization debate around SARS-CoV-2. *J Hosp Infect* 2020;105:381-382.

Gordon J, Darlington O, McEwan P, Lumley M, Taie A, Hicks M, Charbonneau C, Blake A, Hawkins N, Goldenberg S, Otter JA, Wilcox M. Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model. *Pharmacoeconomics* 2020;38:857-869.

Birgand G, Mutter NT, Ahmad R, Tacconelli E, Lucet J-C, Holmes AH, Percept-R Study Group. Risk perception of the antimicrobial resistance by infection control specialists in Europe: a case-vignette study. *Antimicrob Resist Infect Control* 2020;19:33.

Ellington MJ, Davies F, Jauneikaite E, Hopkins KL, Turton JF, Adams G, Pavlu J, Innes AJ, Eades C, Brannigan ET, Findlay J, White L, Bolt F, Kadhani T, Chow Y, Patel B, Mookerjee S, Otter JA, Sriskandan S, Woodford N, Holmes AH. A multi-species cluster of GES-5 carbapenemase producing Enterobacterales linked by a geographically disseminated plasmid. *Clin Infect Dis* accepted.

Birgand G, Troughton R, Marino V, Campbell A, Hettiaratchy S, Hopkins S, Otter JA, Holmes AH. How do surgeons feel about the "Getting it Right First Time" national audit? Results from a qualitative assessment. *J Hosp Infect* 2020;104:328-331.

Vink J, Otter JA, Edgeworth JD. Carbapenemase-Producing Enterobacteriaceae - once positive always positive? *Current Opinion Gastroenterol* 2019 [Epub ahead of print].

Otter JA. How far can improving environmental hygiene REACH in preventing healthcare-associated infections? *Lancet Infect Dis* 2019;19:345-347.

Otter JA, Natale A, Batra R, Tosas Auguste O, Dyakova E, Goldenberg SD, Edgeworth JD. Individual and community-level risk factors for ESBL Enterobacteriaceae colonization identified by universal admission screening in London. *Clin Microbiol Infect* 2019;25:1259-1265.

Patel A, Parikh P, Dunn AN, Otter JA, Thota P, Fraser TG, Donskey CJ, Deshpande A. Effectiveness of daily chlorhexidine bathing for reducing gram-negative infections: A meta-analysis. *Infect Control Hosp Epidemiol* 2019;40:392-399.

Ming DK, Otter JA, Ghani R, Brannigan ET, Boonyasiri A, Mookerjee S, Gilchrist M, Holmes AH, Davies F. The Clinical Risk Stratification and Antibiotic Management of NDM and OXA-48 carbapenemase-producing Enterobacteriaceae bloodstream infections the United Kingdom. *J Hosp Infect* 2019;102:95-9.

Mizuno S, Iwami M, Kunisawa S, Naylor N, Yamashita K, Kyratsis Y, Meads G, Otter JA, Holmes AH, Imanaka Y, Ahmad R. Comparison of national strategies to reduce meticillin-resistant *Staphylococcus aureus* infections in Japan and England. *J Hosp Infect* 2018;100:280-298.

Marbach H, Vizcay-Barrena G, Memarzadeh K, Otter JA, Pathak S, Allaker RP, Edgeworth JD, Harvey RD. Tolerance of MRSA ST239-TW to chlorhexidine-based decolonization; evidence for keratinocyte invasion as a mechanism of biocide evasion. *J Infect* 2019;78:119-126.

Knight GM, Dyakova E, Mookerjee S, Davies F, Brannigan ET, Otter JA, Holmes AH. Fast and expensive (PCR) or cheap and slow (culture)? A mathematical modelling study to explore screening for carbapenem resistance in UK hospitals. *BMC Med* 2018;16:141.

Otter JA, Galletly T, Davies F, Hitchcock J, Gilchrist M, Dyakova E, Mookerjee S, Holmes AH, Brannigan ET. Planning to halve GNBSI: getting to grips with healthcare-associated *Escherichia coli* bloodstream infection sources. *J Hosp Infect* 2018;101:129-133.

Ledwoch K, Dancer SJ, Otter JA, Kerr K, Roposte D, Maillard JY. Beware Biofilm! Dry biofilms containing bacterial pathogens on multiple healthcare surfaces; a multicentre study. *J Hosp Infect* 2018;100:e47-e56.

Mookerjee S, Dyakova E, Davies F, Bamford K, Brannigan ET, Holmes A, Otter JA. Evaluating the benefit of serial screening cultures to detect carbapenemase-producing Enterobacteriaceae (CPE) following hospital admission. *J Hosp Infect* 2018;100:15-20.

Nellums LB, Thompson H, Holmes A, Castro-Sánchez E, Otter JA, Norredam M, Friedland JS, Hargreaves S. Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis. *Lancet Infect Dis* 2018: S1473-3099(18)30219-6.

Hawkey PM, Warren RE, Livermore DM, McNulty CAM, Enoch DA, Otter JA, Wilson APR. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. *J Antimicrob Chemother* 2018;73(Suppl 3):iii2-iii78.

Tosas Auger O, Stabler RA, Betley J, Preston MD, Dhaliwal M, Gaunt M, Ioannou A, Desai N, Keradag T, Batra R, Otter JA, Marbach H, Clark TG, Edgeworth JD. Frequent undetected MRSA ward-based transmission linked to patient sharing between hospitals. *Clin Infect Dis* 2018;66:840-848.

Otter JA, Doumith M, Davies F, Mookerjee S, Dyakova E, Gilchrist M, Brannigan ET, Bamford K, Galletly T, Donaldson H, Aanensen DM, Ellington MJ, Hill R, Turton JF, Hopkins KL, Woodford N, Holmes A. Emergence and clonal spread of colistin resistance due to multiple mutational mechanisms in carbapenemase-producing *Klebsiella pneumoniae* in London. *Sci Rep* 2017;7:12711.

Mitchell BG, Russo PL, Otter JA, Kiernan M, Aveling L. What makes a tweet fly? Analysis of twitter messaging from four infection control conferences. *Infect Control Hosp Epidemiol* 2017;38:1271-1276.

Weber DJ, Otter JA, Rutala WA. Can Copper Coated Surfaces Prevent Healthcare-Associated Infections? *Infect Control Hosp Epidemiol* 2017;38:772-776.

Dyakova E, Bisnauthsing KN, Querol-Rubiera A, Patel A, Ahanonu C, Tosas Auguet O, Edgeworth JD, Goldenberg SD, Otter JA. Efficacy and acceptability of rectal and perineal sampling for identifying gastrointestinal colonisation with ESBL-Enterobacteriaceae. *Clin Microbiol Infect* 2017;23:577.e1-577.e3.

Marbach H, Boakes E, Lynham S, Ward M, Otter JA, Edgeworth JD. Identification of a distinctive phenotype for endocarditis-associated clonal complex 22 MRSA isolates with reduced vancomycin susceptibility. *J Med Microbiol* 2017 66:584-591.

Keward J, Bradshaw P, Otter JA. Reducing the number of missed isolation days in a paediatric high-dependency unit using semi-permanent pods. *J Infect Prevent* 2017;18:67-71.

Otter JA, Burgess P, Davies F, Mookerjee S, Gilchrist M, Parsons D, Brannigan ET, Robotham JV, Holmes AH. Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: an economic evaluation from a hospital perspective. *Clin Microbiol Infect* 2017;23:188-196.

Boakes E, Marbach H, Lynham S, Ward M, Edgeworth JD, Otter JA. A comparative analysis of Phenol Soluble Modulin production and *G. mellonella* killing by community-associated and healthcare-associated MRSA strains. *J Med Microbiol* 2016;65:1429-1433.

Otter JA, Dyakova E, Bisnauthsing K, Querol-Rubiera A, Patel A, Ahanonu C, Tosas Auguet O, Edgeworth J, Goldenberg S. Universal hospital admission screening for carbapenemase-producing organisms in a low prevalence setting. *J Antimicrobial Chemother* 2016;71:3556-3561.

McCord J, Prewitt M, Dyakova E, Mookerjee S, Otter JA. Reduction in *Clostridium difficile* infection (CDI) associated with the introduction of hydrogen peroxide vapor (HPV) automated room disinfection. *J Hosp Infect* 2016;94:185-187.

Otter JA. Interpreting the guidelines for cleaning up after carbapenemase-producing organisms: the devil's in the dilution. *J Hosp Infect* 2016;94:108-109.

Vella V, Moore LSP, Robotham J, Davies F, Birgand GJC, Otter JA, Brannigan E, Dyakova E, Knight GM, Mookerjee S, Holmes AH. Vella V, Moore LSP, Robotham J, Davies F, Birgand GJC, Otter JA, Brannigan E, Dyakova E, Knight GM, Mookerjee S, Holmes AH. Demand and capacity for carbapenemase-producing Enterobacteriaceae screening in a West London hospital network. *J Hosp Infect* 2016;94:118-124.

Brown C, Livermore DM, Otter JA, Warren RE, Jenks P, Enoch DA, Newsholme W, Oppenheim B, Leanord A, McNulty C, Tanner G, Bennett S, Cann M, Bostock J, Collins E, Peckitt S, Ritchie L, Fry C, Hawkey P, Wilson AP. Multidrug-resistant (MDR) Gram-negative bacteria information leaflets. *J Hosp Infect* 2016;92:86-87.

Tosas Auguet O, Betley J, Patel A, Marbach H, Stabler R, Hern P, Ayree A, Otter JA, Goldenberg SD, Desai N, Karadag T, Grundy C, Gaunt M, Cooper B, Edgeworth J, Kypraios T. Evidence for community

transmission of community-associated but not health-care-associated methicillin-resistant *Staphylococcus aureus* strains linked to social and material deprivation: spatial analysis of cross-sectional data. *Plos Med* 2016;13:e1001944.

Horn K, Otter JA. Hydrogen peroxide vapor room disinfection and hand hygiene improvements reduce *Clostridium difficile* infection, MRSA, VRE and ESBL by 47%. *Am J Infect Control* 2015;43:1354-1356.

Wilson APR, Livermore DM, Otter JA, Warren RE, Jenks P, Enoch DA, Newsholme, Oppenheim B, Leanord A, McNulty C, Tanner G, Bennett S, Cann M, Bostock J, Collins E, Peckitt S, Ritchie L, Fry C, Hawkey PM. Prevention and control of multiresistant Gram-negative bacteria – recommendations from a Joint Working Party. *J Hosp Infect* 2016 Jan;Suppl 1:S1-S44.

Hughes J, Goldenberg SD, Tosas O, Edgeworth JD, Otter JA. Recent emergence of carbapenem-resistant organisms in a low prevalence UK setting in London. *J Infect Prevent* 2016;17:130-134.

Otter JA. Reflections from Infection Prevention 2015: beating the bugs, improving the systems and thinking outside the box. *J Infect Prevent* 2016;17:37-41.

Otter JA, Donskey CJ, Yezli S, Douthwaite S, Goldenberg SD, Weber DJ. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. *J Hosp Infect* 2016;92:235-250.

Otter JA, Mephram S, Athan B, Mack D, Smith R, Jacobs M, Hopkins S. Terminal decontamination of the Royal Free London High Level Isolation Unit (HLIU) following a case of Ebola virus disease using hydrogen peroxide vapour. *Am J Infect Control* 2016;44:233-235.

Fisher D, Long P, Salmon S, Teo C, Cook A, Otter JA. Where's all the VRE gone? A successful VRE bundle at a Singapore hospital. *Infect Control Hosp Epidemiol* 2016;37:107-109.

Otter JA, Mutters N, Tacconelli E, Gikas A, Holmes AH. Controversies in guidelines for the control of multidrug-resistant Gram-negative bacteria in EU countries. *Clin Microbiol Infect* 2015;21:1057-1066.

Otter JA. Biofilms mean that the 'environmentome' of hospital surfaces is teeming with life. *J Hosp Infect* 2015;91:218-219.

Otter JA. The inaugural Healthcare Infection Society Middle East Summit: 'No action today. No cure tomorrow. *J Hosp Infect* 2015;91:199-201.

Hughes J, Stabler R, Karadag T, Desai N, Patel A, Otter JA, Edgeworth JD, Tosas August O. Clonal variation in high- and low-level phenotypic and genotypic mupirocin resistance of MRSA isolates in South East London. *J Antimicrobial Chemother* 2015;70:3191-3199.

Biswas J, Patel A, Otter JA, van Kleef E, Goldenberg SD. Significant contamination of the hospital environment from potential *Clostridium difficile* excretors. *Infect Control Hosp Epidemiol* 2015;36:975-977.

Biswas J, Patel A, Otter JA, Wade P, Newsholme W, Goldenberg SD. Reduction in *Clostridium difficile* environmental contamination in hospitalised patients treated with fidaxomicin. *J Hosp Infect* 2015;90:267-270.

Otter JA. What's trending in the infection prevention and control literature? From HIS 2012 to HIS 2014, and beyond. *J Hosp Infect* 2015;89:229-236.

Lemmen S, Scheithauer S, Häfner H, Yezli S, Mohr M, Otter JA. Evaluation of hydrogen peroxide vapour for the inactivation of nosocomial pathogens on porous and non-porous surfaces. *Am J Infect Control* 2015;43:82-85.

Otter JA, Vickery K, Walker J, deLancey-Pulcini E, Stoodley P, Salkeld JA, Chewins J, Yezli S, Edgeworth JD. Surface-attached cells, biofilms and biocide susceptibility: implications for hospital cleaning and disinfection. *J Hosp Infect* 2015;89:16-27.

Yezli S, Otter JA. Does the inanimate environment play a role in the transmission of pathogens in operating room? *Surg Infect* 2014;15:694-699.

Curran E, Otter JA. How to prevent and control outbreaks of carbapenem-resistant Enterobacteriaceae. *J Infect Prevent* 2014;15:193-198.

Otter JA, Tosas O, Herdman MT, Williams B, Tucker D, Edgeworth JD, French GL. Implications of targeted versus universal admission screening for meticillin-resistant *Staphylococcus aureus* carriage in a London hospital. *J Hosp Infect* 2014;87:171-174.

O'Halloran PD, Winter PK, Otter JA, Adams NMT, Chewins J. Aqueous oxygen peroxide treatment of venous leg ulcers is associated with improved wound healing in a primary care based randomised, double-blind, placebo-controlled trial. *J Wound Care* 2014;23:176-190.

Goyal SM, Chander Y, Yezli S, Otter JA. Evaluating the virucidal efficacy of hydrogen peroxide vapor (HPV). *J Hosp Infect* 2014;86:255-259.

Otter JA, Davies B, Menson E, Klein JL, Watts TL, Kearns AM, Pichon B, Edgeworth JD, French GL. Identification and control of a gentamicin-resistant, meticillin-susceptible *Staphylococcus aureus* outbreak on a neonatal unit. *J Infect Prevent* 2014;15:104-109.

Havill NL, Boyce JM, Otter JA. Extended survival of carbapenem-resistant Enterobacteriaceae on dry surfaces. *Infect Control Hosp Epidemiol* 2014;35:445-447.

Otter JA. Infection Prevention 2013 – a potted overview. *J Infect Prevent* 2014;15:9.

Otter JA, Yezli S, Perl TM, Barbut F, French GL. A request for an alliance in the battle for clean and safe hospital surfaces. *J Hosp Infect* 2013;84:341-342.

Otter JA, Nowakowski E, Salkeld JAG, Duclos M, Passaretti CL, Yezli S, Ross T, Carroll KC, Perl TM. Saving costs through the decontamination of the packaging of unused medical supplies using hydrogen peroxide vapor. *Infect Control Hosp Epidemiol* 2013;34:472-478.

Otter JA, Yezli S, Salkeld JAG, French GL. Evidence that contaminated surfaces contribute to the transmission of hospital pathogens and an overview of strategies to address contaminated surfaces in hospital settings. *Am J Infect Control* 2013;41:S6-S11.

Barbut F, Yezli S, Otter JA. Hydrogen peroxide room disinfection: there is no elephant in the room but there's plenty of evidence in the trunk. *J Hosp Infect* 2013;83:355-356.

Otter JA, Patel A, Cliff P, Halligan E, Tosas O, Edgeworth JD. Selection for qacA carriage in CC22 but not CC30 MRSA bloodstream infection isolates during a successful institutional infection control programme. *J Antimicrob Chemother* 2013;68:992-999.

Otter JA, Herdman MT, Williams B, Tosas O, Edgeworth JD, French GL. Low prevalence of meticillin-resistant *Staphylococcus aureus* carriage at hospital admission: implications for risk factor based vs. universal screening. *J Hosp Infect* 2013;83:114-121.

Otter JA. How do we tackle contaminated hospital surfaces? *Healthcare Infect* 2013;18:42-44.

Otter JA, Yezli S, Perl TM, Barbut F, French GL. The role of 'no-touch' automated room disinfection systems in infection prevention and control. *J Hosp Infect* 2013;83:1-13.

Passaretti CL, Otter JA, Reich NG, Myers J, Shepard J, Howard T, Carroll KC, Lipsett P, Perl TM. Environmental decontamination with hydrogen peroxide vapor reduces the risk of patient acquisition of multidrug-resistant organisms. *Clin Infect Dis* 2013;56:27-35.

Barbut F, Yezli S, Mimoun M, Pham J, Chaouat M, Otter JA. Reducing the spread of *Acinetobacter baumannii* and methicillin-resistant *Staphylococcus aureus* on a burns unit through the intervention of an infection control bundle. *Burns* 2013;39:395-403.

Otter JA. Hospital infection control in 2012: new solutions for old and resurgent problems. *J Healthcare Associated Infect* 2012;5:68-72.

Otter JA, Yezli S, French GL. The impact of the suspending medium on the susceptibility of methicillin-resistant *Staphylococcus aureus* to hydrogen peroxide vapour (HPV) decontamination. *J Hosp Infect* 2012;82:213-215.

Yezli S, Otter JA. Does the discovery of biofilms on dry hospital environmental surfaces change the way we think about hospital disinfection? *J Hosp Infect* 2012;81:293-294.

Otter JA, French GL. Community-associated methicillin-resistant *Staphylococcus aureus*: the case for a genotypic definition. *J Hosp Infect* 2012;81:143-8. [Selected as one of the top 10 papers of the year by the editor: <http://www.journalofhospitalinfection.com/content/editors-choice>]

Otter JA, Yezli S. Are commercially available *Geobacillus stearothermophilus* biological indicators an appropriate standard for hydrogen peroxide vapour systems in hospitals? *J Hosp Infect* 2012;80:272-273.

Miller CE, Batra R, Copper BS, Patel AK, Klein J, Otter JA, Kypraios T, French GL, Tosas O, Edgeworth JD. An association between bacterial genotype combined with a high-vancomycin minimum inhibitory concentration and risk of endocarditis in methicillin-resistant *Staphylococcus aureus* bloodstream infection. *Clin Infect Dis* 2012;54:591-600.

Barbut F, Yezli S, Otter JA. The in vitro activity of hydrogen peroxide vapour (HPV) against *Clostridium difficile* spores. *J Hosp Infect* 2012;80:85-87.

Otter JA, French GL. Community-associated methicillin-resistant *Staphylococcus aureus* strains as a cause of healthcare-associated infection. *J Hosp Infect* 2011;79:189-193.

- Yezli S, Otter JA. Minimum infective dose of the major human respiratory and enteric viruses transmitted through food and the environment: a review. *Food Environ Virol* 2011;3:1-30.
- Otter JA, Yezli S, French GL. The role of contaminated surfaces in the transmission of nosocomial pathogens. *Infect Control Hosp Epidemiol* 2011;32:687-699.
- Berrie E, Andrews L, Yezli S, Otter JA. Hydrogen peroxide vapour (HPV) inactivation of adenovirus. *Lett Applied Micro* 2011;52:555-558.
- Cooper T, O'Leary M, Yezli S, Otter JA. The impact of environmental decontamination using hydrogen peroxide vapour on the incidence of *Clostridium difficile* infection in one hospital trust. *J Hosp Infect* 2011;78:238-240.
- Otter JA, French GL. Utility of antimicrobial susceptibility based algorithms for the presumptive identification of genotypically-defined community-associated methicillin-resistant *Staphylococcus aureus* at a London teaching hospital. *Eur J Clin Microbiol Infect Dis* 2011;30:459-463.
- Otter JA, Yezli S. A call for clarity when discussing hydrogen peroxide vapour and aerosol systems. *J Hosp Infect* 2011;77:83-84.
- Otter JA, Passaretti CL, Ross T, Carroll KC, French GL, Perl TM. Low frequency of environmental contamination with methicillin-resistant *Staphylococcus aureus* in an inner city emergency department and an HIV outpatient clinic. *Am J Infect Control* 2011;39:151-153.
- Otter JA, Havill NL, Boyce JM. Hydrogen peroxide vapor is not the same as aerosolized hydrogen peroxide. *Infect Control Hosp Epidemiol* 2010;11:1201-1202.
- Otter JA, Yezli S, Schouten MA, van Zanten ARH, Houmes-Zielman G, Nohlmans-Paulssen. Hydrogen peroxide vapor (HPV) decontamination of an intensive care unit to remove environmental reservoirs of multidrug-resistant Gram-negative rods during an outbreak. *Am J Infect Control* 2010;38:754-756.
- Otter JA, Yezli S. Cycle times for hydrogen peroxide vapour decontamination. *Can J Microbiol* 2010;56:356-257.
- Otter JA, Barnicoat M, Down J, Smyth D, Yezli S, Jeanes A. Hydrogen peroxide vapour (HPV) decontamination of an intensive care unit room used to treat a patient with Lassa fever. *J Hosp Infect* 2010;75:335-337.
- Otter JA, French GL. The molecular epidemiology of community-associated methicillin-resistant *Staphylococcus aureus* in Europe. *Lancet Infect Dis* 2010;10:227-239.
- Otter JA, Kearns AM, French GL, Ellington MJ. Panton-Valentine leukocidin encoding bacteriophage and gene sequence variation in community-associated methicillin-resistant *Staphylococcus aureus*. *Clin Microbiol Infect* 2010;16:68-73.
- Otter JA, French GL. Bacterial contamination on touch surfaces in the public transport system and in public areas of a hospital in London. *Lett Appl Microbiol* 2009;49:803-805.
- Otter JA, Havill NL, Adams NMT, Cooper TC, Tauman A, Boyce JM. Environmental sampling for *Clostridium difficile*: swabs or sponges? *Am J Infect Control* 2009;37:517-518.

Otter JA, Puchowicz M, Ryan D, Salkeld JA, Cooper TA, Havill NL, Tuozzo K, Boyce JM. Feasibility of routinely using hydrogen peroxide vapor to decontaminate rooms in a busy United States hospital. *Infect Control Hosp Epidemiol* 2009;30:574-547.

Otter JA, Budde-Niekiet A. Hydrogen peroxide vapor: a novel method for the environmental control of lactococcal bacteriophages. *J Food Prot* 2009;72:412-414.

Otter JA, Havill NL, Boyce JM, French GL. Comparison of community-associated methicillin-resistant *Staphylococcus aureus* from teaching hospitals in London and the USA, 2004-2006: where is USA300 in the UK? *Eur J Clin Microbiol Infect Dis* 2009;28:835-839.

Otter JA, French GL. Survival of nosocomial bacteria and spores on surfaces and inactivation by hydrogen peroxide vapour (HPV). *J Clin Microbiol* 2009;47:205-207.

Boyce JM, Havill NL, Otter JA, McDonald LC, Adams NM, Thompson A, Wiggs L, Noble-Wang J. Impact of hydrogen peroxide vapor room decontamination on *Clostridium difficile* environmental contamination and transmission in a healthcare setting. *Infect Cont Hosp Epidemiol* 2008;29:723-729.

Otter JA, French GL. The emergence of community-associated methicillin-resistant *Staphylococcus aureus* (CA-MRSA) at a London Teaching Hospital, 2000-2006. *Clin Microbiol Infect* 2008;14:670-676.

Otter JA, French GL. Community-associated methicillin-resistant *Staphylococcus aureus* in injecting drug users and the homeless in south London. *J Hosp Infect* 2008;69:198-200.

Dryden M, Parnaby R, Dailly S, Lewis T, Davis-Blues K, Otter JA, Kearns AM. Hydrogen peroxide vapor (HPV) decontamination in the control of a polyclonal MRSA outbreak on a surgical ward. *J Hosp Infect* 2008;68:190-192.

Hall L, Otter JA, Chewins J, Wengenack NL. Deactivation of the dimorphic fungi *Histoplasma capsulatum*, *Blastomyces dermatitidis* and *Coccidioides immitis* using hydrogen peroxide vapor. *Med Mycol* 2008;46:189-191.

Otter JA, Chewins J, Windsor D, Windsor H. Microbial contamination in cell culture: a potential role for hydrogen peroxide vapour (HPV)? *Cell Biol Int* 2008;32:326-327.

Otter JA, Klein J, Watts T, Kearns AM, French GL. Identification and control of an outbreak of ciprofloxacin-susceptible EMRSA-15 on a neonatal unit. *J Hosp Infect* 2007;67:232-239.

Otter JA, Cummins M, Ahmad F, van Tonder C, Drabu YJ. Assessing the biological efficacy and rate of recontamination following hydrogen peroxide vapour decontamination. *J Hosp Infect* 2007;67:182-188.

Boyce JM, Havill NL, Otter JA, Adams NM. Widespread environmental contamination associated with patients with diarrhea and methicillin-resistant *Staphylococcus aureus* colonization of the gastrointestinal tract. *Infect Control Hosp Epidemiol* 2007; 28:1142-1147.

Otter JA, Havill NL, Boyce JM. Evaluation of real-time polymerase chain reaction for detection of methicillin-resistant *Staphylococcus aureus* on environmental surfaces. *Infect Cont Hosp Epidemiol* 2007;28:1003-1005.

Hall L, Otter JA, Chewins J, Wengenack NL. Use of hydrogen peroxide vapour for deactivation of *Mycobacterium tuberculosis* in a biological safety cabinet and a room. *J Clin Microbiol* 2007;45:810-815.

Otter JA, French GL. Nosocomial transmission of community-associated methicillin-resistant *Staphylococcus aureus*: an emerging threat. *Lancet Infect Dis* 2006;6:753-755.

Otter JA, French GL, Adams NM, Watling D, Parks MJ. Hydrogen peroxide vapour decontamination in an overcrowded tertiary care referral centre: some practical answers. *J Hosp Infect* 2006;62:384-385.

Otter JA. Bio-deactivation of hospital pathogens. *Health Estate* 2005;59:41-44.

Johnston MD, Lawson S, Otter JA. Evaluation of hydrogen peroxide vapour as a method for the decontamination of surfaces contaminated with *Clostridium botulinum* spores. *J Microbiol Methods* 2005;60:403-411.

French GL, Otter JA, Shannon KP, Adams NM, Watling D, Parks MJ. Tackling contamination of the hospital environment by methicillin-resistant *Staphylococcus aureus* (MRSA): a comparison between conventional terminal cleaning and hydrogen peroxide vapour decontamination. *J Hosp Infect* 2004;57:31-37.